Praxis Precision Medicines, Inc. (PRAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$351.81-0.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PRAX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -31.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PRAX — legal / regulatory event — Changes in Registrant's Certifying Accountant
Dated 2026-07-02
Changes in Registrant's Certifying Accountant. Dismissal of Independent Registered Public Accounting Firm On June 29, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of Praxis Precision Medicines, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm, effective as of that date. The reports of EY on the Company's financial statements for the fiscal years ended December 31, 2025 and Dece…
Why it matters: The recent trial results are crucial for the future of the drug. Positive updates can boost confidence.
Supportive ifA press release states that the Phase 2/3 POWER1 study met its primary success measure.
Worry ifRecent updates show the trial keeps missing important success goals.
Why it matters: This date is important for relutrigine's approval. Approval would add to Praxis's products.
Supportive ifThe FDA approves relutrigine for SCN2A and SCN8A DEEs by December 27, 2026.
Worry ifThe FDA might reject relutrigine. They could also delay approval past December 27, 2026.
Why it matters: These results will show how well vormatrigine works for focal onset seizures. Positive results could boost confidence in the drug's potential.
Supportive ifThe POWER1 study shows a big drop in seizures compared to placebo.
Worry ifResults from the POWER1 study do not meet the primary success measure.
Why it matters: Restarting the POWER2 study may show renewed confidence in vormatrigine. This affects its future.
Watch forPraxis announces the restart of the POWER2 study with good updates.
Also watch forPraxis delays or cancels the restart of the POWER2 study.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $588 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,261 loss on $10,000 · 32.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good results could help relutrigine's NDA. This would improve its market chances.
Supportive ifThe EMERALD study shows good results for relutrigine.
Worry ifEMERALD study results are bad or unclear.
Why it matters: Keeping cash until 2028 is important for ongoing operations and trials. Changes could mean financial trouble.
Worry ifPraxis confirms cash and investments remain at or above $1.4 billion.
Less concerning ifCash and investments fall below what is needed to keep operations running until 2028.
Why it matters: Good results could help relutrigine enter the market and boost sales. It shows Praxis's pipeline strength.
Supportive ifEMERALD study shows positive topline results in Q4 2026.
Worry ifEMERALD study results are not good or are unclear.